Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seelos reports positive SLS-002 data showing treatment benefit in suicidal behavior in depression patients
https://ih.advfn.com/p.php?pid=nmona&article=85126280
Positive clinical data and the stock gets torched. Da fug you say!
What do you mean? This stock has been pro ported to hit Fifteen!!
Latest buy $4.35.
$SEEL is on the rise again!
3 Penny Stocks To Watch As Biotech Jumps In April 2021
Seelos Therapeutics Inc.
Seelos Therapeutics is another pure-play biotech stock that we’ve been discussing for several months. However, it’s worth noting that SEEL is working on one non-traditional compound that could play out well in the long run. This is SLS-002 or intranasal racemic ketamine.
Currently, it has two investigational new drug applications for SLS-002 in the treatment of both Acute Suicidal Ideation and Behavior in Major Depressive Disorder/PTSD. In 2019, the U.S. saw more than 1 million visits to the emergency room for suicidal attempts. Because of this, Seelos sees a large market opportunity to potentially treat these patients.
It’s worth considering that there are some stigmas around ketamine as a pharmaceutical. However, early studies are showing highly encouraging efficacy levels. In a recent development, Seelos announced a strategic device partnership with AptarGroup Inc. (NYSE: ATR). This partnership covers the BDS Liquid System, used in the intranasal delivery of SLS-002.
Raj Mehra, Ph.D., the Chairman and CEO of Seelos, states that “Aptar is a world-class organization and has been an integral partner for our intranasal ketamine program since our inception. This partnership strengthens the collaboration between Seelos and Aptar, and further protects the SLS-002 franchise.â€
With the Part 1, 16-patient proof-of-concept study now completed, Seelos should have open-label data by the second quarter of this year. While many biotech companies are engaged in exciting studies, this one is quite different from the rest.
It’s worth considering that it may take some time for this study to be completed. However, with Canada and several U.S. states legalizing certain psychedelic compounds, we could see widespread adoption of new types of pharmaceuticals in the coming years. This has helped to usher in a new era of psychedelic penny stocks. Considering this, is SEEL stock worth watching?
DEF 14A today.
https://seekingalpha.com/filing/5474869
Thanks, thought that article had some sort of connection to the company. All good
SEEL is conducting a few trials for treatment of Parkinson’s.
See Seelos Path, Our Focus: Parkinson’s Disease
https://seelostherapeutics.com/the-seelos-path-copy/
Thanks for sharing this, can you please tell me how this is connected to Seelos? Thanks
Asked about the future of Parkinson’s disease in the US, Dr Ray Dorsey says, “We’re on the tip of a very, very large iceberg.”
Dorsey, a neurologist at the University of Rochester Medical Center and author of Ending Parkinson’s Disease, believes a Parkinson’s epidemic is on the horizon. Parkinson’s is already the fastest-growing neurological disorder in the world; in the US, the number of people with Parkinson’s has increased 35% the last 10 years, says Dorsey, and “We think over the next 25 years it will double again.”
$SEEL is heading up in the market this morning after announcing agreements surrounding the delivery of SLS-002. https://cnafinance.com/seel-stock-heres-why-seelos-therapeutics-is-up/
SEEL bounced down off resistance point.
Top 20 Institutions own 7M SEEL shares.
Top 20 Funds own 3.7M SEEL shares.
https://www.morningstar.com/stocks/xnas/seel/ownership
B. Riley initiated coverage on shares of Seelos Therapeutics (NASDAQ:SEEL) in a research note issued to investors on Tuesday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $15.00 price target on the stock.
Several other brokerages also recently commented on SEEL. Zacks Investment Research raised shares of Seelos Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 13th. BTIG Research initiated coverage on shares of Seelos Therapeutics in a report on Wednesday, March 17th. They issued a buy rating and a $14.00 price target on the stock.
https://www.tickerreport.com/banking-finance/7239199/seelos-therapeutics-nasdaqseel-now-covered-by-analysts-at-b-riley.html
5.21! Here come the big buys!
IMO GLTA
Guess I shouldn’t have sold my 5000 shares at a 1.86 during the last run up. Held them for years. Saw ketamine treatment as a big market for mental illness, but the constant dilution during each run up had me fed up. Oh well.
"Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Long term indicators fully support a continuation of the trend."
https://www.barchart.com/stocks/quotes/SEEL/overview
GLTA
Wait for PM tomorrow!
IMO GLTA
GO SEEL!!!
GLTA
$SEEL is screaming for the top after a B. Riley analyst initiated coverage with a Buy rating and a $15 price target. https://cnafinance.com/seel-stock-seelos-therapeutics-climbs-on-analyst-coverage/
Seelos Therapeutics (SEEL) received a Buy rating and a $15.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares closed last Monday at $4.26.
I feel so alone here, lol. Go SEEL!
Shorts are fooked.
IMO GLTA
GO SEEL! Hope there's some great news this week.
GLTA
I hear the Jaws theme...
Seels easily outmanouver sharks/shorts
LOL...GLTA
Very nice close! News must be on the horizon. Fingers crossed.
IMO GLTA
A short few weeks ago volume was well over 300 million. Hope to see that again when we get some news!
IMO GLTA
Very high volume, 5.3M.
Time to buy more?
The next few weeks should be exciting. Don't ask me why. ALWAYS do your own DD.
IMO GLTA
Followers
|
245
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30373
|
Created
|
09/14/05
|
Type
|
Free
|
Moderators |
Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.
By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications.
Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.
We invite you to stay update on the progress of our assets in our clinical development programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |